Huertas-Caro Carlos Alexander, Ramirez Mayra Alejandra, Gonzalez-Torres Henry J, Sanabria-Salas María Carolina, Serrano-Gómez Silvia J
Grupo de investigación en biología del cáncer, Instituto Nacional de Cancerología, Bogotá, Colombia.
Doctorado en Ciencias Biomédicas, Universidad del Valle, Cali, Colombia.
Front Oncol. 2022 Jul 18;12:910976. doi: 10.3389/fonc.2022.910976. eCollection 2022.
Triple-negative breast cancer (TNBC) occurs more frequently in young (<50 years) non-Hispanic black and Hispanic/Latina women. It is considered the most aggressive subtype of breast cancer, although, recently, immune infiltrate has been associated with long-term survival, lower risk of death and recurrence, and response to neoadjuvant chemotherapy. The aim of this review was to evaluate the clinical impact of the immune infiltrate in TNBC by discussing whether its prognostic value varies across different populations. A comprehensive systematic search in databases such as PubMed and Web of Science was conducted to include papers focused on tumor-infiltrating lymphocytes (TILs) in TNBC in different population groups and that were published before January 2021. TNBC patients with higher levels of TILs had longer overall survival and disease-free survival times compared with TNBC patients with low TIL levels. Similar results were observed for CD4+, CD8+ TIL populations. On the other hand, patients with high TIL levels showed a higher rate of pathological complete response regardless of the population group (Asian, European, and American). These results altogether suggest that TIL subpopulations might have a prognostic role in TNBC, but the underlying mechanism needs to be elucidated. Although the prognosis value of TILs was not found different between the population groups analyzed in the revised literature, further studies including underrepresented populations with different genetic ancestries are still necessary to conclude in this regard.
三阴性乳腺癌（TNBC）在年轻（<50岁）的非西班牙裔黑人及西班牙裔/拉丁裔女性中更为常见。它被认为是乳腺癌中最具侵袭性的亚型，不过，最近免疫浸润已与长期生存、较低的死亡和复发风险以及对新辅助化疗的反应相关联。本综述的目的是通过讨论免疫浸润的预后价值在不同人群中是否存在差异，来评估其在TNBC中的临床影响。我们在PubMed和Web of Science等数据库中进行了全面的系统检索，纳入了2021年1月之前发表的、聚焦于不同人群组TNBC中肿瘤浸润淋巴细胞（TILs）的论文。与TIL水平低的TNBC患者相比，TIL水平高的TNBC患者总体生存期和无病生存期更长。对于CD4 +、CD8 + TIL群体也观察到了类似结果。另一方面，无论人群组（亚洲、欧洲和美洲）如何，TIL水平高的患者病理完全缓解率更高。这些结果共同表明，TIL亚群可能在TNBC中具有预后作用，但其潜在机制仍需阐明。尽管在修订文献中分析的人群组之间未发现TILs的预后价值存在差异，但仍需要进一步开展研究，纳入不同遗传血统且代表性不足的人群，才能在这方面得出结论。
